- GlaxoSmithKline remains a high-yield pick in pharma, partially a consequence of several years of little growth and portfolio attrition to generics.
- Recent waves of drugs falling off-patent leave a substantial portfolio with a long while till patents expire.
- With three promising approvals coming up in the next 2-3 years, and growing stability in the off-patent portfolio, growth could start.
- We think that it's not going to take much for dividend growth to start, and it'll have been accomplished organically.
For further details see:
GlaxoSmithKline: Growth Only A Couple Of Years Away